Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > CD40 Ligand

CD40 Ligand

Brief Information

Name:CD40 ligand
Target Synonym:CD154 Antigen,HCD40L,CD154,TNFSF5,CD40L,CD40 ligand, soluble form,CD40 ligand, membrane form,Tumor necrosis factor ligand superfamily member 5,T-cell antigen Gp39,CD40-L,CD40LG,TNF-Related Activation Protein,Tumor Necrosis Factor (Ligand) Superfamily Member 5,T-B Cell-Activating Molecule,T-BAM,HIGM1,Gp39,IMD3,IGM,CD40 Ligand,CD40 Antigen Ligand,TRAP,Tumor Necrosis Factor (Ligand) Superfamily, Member 5 (Hyper-IgM Syndrome),Hyper-IgM Syndrome,sCD40L
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CDL-H5269-Cell-based assay
 CD40 Ligand FACS

FACS analysis shows that Human CD40 Ligand Protein, Fc Tag, premium grade (Cat. No. CDL-H5269) can bind to 293T-CD40 cells surface CD40. The concentration of Human CD40 Ligand is 0.3 μg/mL (Routinely tested).

CDL-H5264-Cell-based assay
 CD40 Ligand CELL

Human CD40 Ligand Protein, Fc Tag (N297A), premium grade (Cat. No. CDL-H5264) stimulates Human CD40 (Luc) HEK293 Reporter Cell. The EC50 value of this effect is 13.79 ng/mL (Routinely tested).

 CD40 Ligand BLI

Loaded Human CD40, Fc Tag (Cat. No. CD0-H5253) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag, premium grade (Cat. No. CDL-H52Db) with an affinity constant of 1.58 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

 CD40 Ligand ELISA

Immobilized Human CD40, Mouse IgG2a Fc Tag, low endotoxin (MALS verified) (Cat. No. CD0-H525a) at 5 μg/mL (100 μL/well) can bind Rabbit CD40 Ligand, His,Flag Tag (Cat. No. CD0-R52D9) with a linear range of 1-39 ng/mL (QC tested).

Synonym Name



CD40 ligand is also known as CD40L, CD154, TNFSF5 and T-cell antigen Gp39, is a single-pass type I I membrane protein which belongs to the TNF superfamily of molecules. CD40 ligand is expressed predominantly on activated CD4+ T lymphocytes, and also found in other types of cells, including platelets, mast cells, macrophages, basophils, NK cells, B lymphocytes, as well as non-haematopoietic cells (smooth muscle cells, endothelial cells, and epithelial cells). Although all monomeric, dimeric and trimeric forms of soluble CD40 ligand can bind to CD40, the trimeric form of soluble CD40 ligand has the most potent biological activity through oligomerization of cell surface CD40, a common feature of TNF receptor family members.CD40 ligand binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. In general, CD40 ligand plays the role of a costimulatory molecule and induces activation in APC in association with T cell receptor stimulation by MHC molecules on the APC. In total CD40 ligand has three binding partners: CD40, α5β1 integrin and αIIbβ3. CD40 ligand regulates B cell function by engaging CD40 on the B cell surface. A defect in this gene results in an inability to undergo immunoglobulin class switch and is associated with hyper IgM syndrome.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Dapirolizumab pegol Anti-CD40L-Fab; Anti-CD40L-Fab-PEG; CDP-7657; CD40L - Fab; BIIB-133 Phase 3 Clinical Biogen Inc, Ucb Autoimmune Diseases; Connective Tissue Diseases; Immune System Diseases; Lupus Erythematosus, Systemic; Skin and Connective Tissue Diseases Details
Dazodalibep VIB-4920; MEDI-4920; HZN-4920(Horizon Therapeutics); UNII-HN5US76BWF; WHO-11399 Phase 3 Clinical Medimmune Llc, Horizon Therapeutics PLC Rejection of renal transplantation; Sjogren's Syndrome; Arthritis, Rheumatoid; Rejection of organ transplantation; Lupus Nephritis; Sjogren-Larsson Syndrome Details
Frexalimab INX-021; SAR-441344 Phase 3 Clinical Immunext Inc Diabetes Mellitus, Type 1; Sjogren's Syndrome; Multiple Sclerosis; Lupus Erythematosus, Systemic; Sjogren-Larsson Syndrome Details
Anti-CD40L antibody (Bristol-Myers Squibb) Phase 2 Clinical Bristol-Myers Squibb Company Immunologic Deficiency Syndromes Details
AdCD40L Phase 2 Clinical Uppsala University Urinary Bladder Neoplasms; Melanoma Details
Tegoprubart AT-1501 Phase 2 Clinical Als Therapy Development Institute Diabetes Mellitus, Type 1; Rejection of renal transplantation; Glomerulonephritis, IGA; Diabetes Mellitus; Amyotrophic Lateral Sclerosis Details
Delolimogene mupadenorepvec LOAd-703 Phase 2 Clinical Uppsala University, Lokon Pharma Biliary Tract Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma Details
CD40 ligand expressing MSLN-CAR T cells Phase 2 Clinical Pla General Hospital Solid tumours Details
CD40L-augmented Tumor Infiltrating Lymphocytes (H Lee Moffitt Cancer Center & Research Institute) Phase 2 Clinical H Lee Moffitt Cancer Center & Research Institute Carcinoma, Non-Small-Cell Lung Details
Letolizumab BMS-986004; BMS2h-572-633-CT-L2 Phase 1 Clinical Bristol-Myers Squibb Company Purpura, Thrombocytopenic, Idiopathic; Graft vs Host Disease Details
TNX-1500 TNX-1500 Phase 1 Clinical Tonix Pharmaceuticals Holding Corp Autoimmune Diseases; Rejection of organ transplantation; Autoimmune Diseases of the Nervous System Details
MEM-288 MEM-288 Phase 1 Clinical Memgen Solid tumours; Head and Neck Neoplasms; Carcinoma, Merkel Cell; Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma Details
IBI355 IBI-355 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Sjogren's Syndrome; Lupus Erythematosus, Systemic Details
APB-A1 APB-A1; Lu-AG22515 Phase 1 Clinical AprilBio Co Ltd Neuromyelitis Optica Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken